biomedicines Article Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor Francisco Javier Gil-Etayo 1,† , Sara Garcinuño 2,†, Antonio Lalueza 3 , Raquel Díaz-Simón 3, Ana García-Reyne 3, Daniel Enrique Pleguezuelo 1 , Oscar Cabrera-Marante 1, Edgard Alfonso Rodriguez-Frias 1, Alfredo Perez-Rivilla 4, Manuel Serrano 5 and Antonio Serrano 1,2,6,* 1 Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain;
[email protected] (F.J.G.-E.);
[email protected] (D.E.P.);
[email protected] (O.C.-M.);
[email protected] (E.A.R.-F.) 2 Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain;
[email protected] 3 Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain;
[email protected] (A.L.);
[email protected] (R.D.-S.);
[email protected] (A.G.-R.) 4 Department of Microbiology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain;
[email protected] 5 Department of Immunology, Hospital Universitario Clínico San Carlos, 28041 Madrid, Spain;
[email protected] 6 Department of Epidemiology, Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain Citation: Gil-Etayo, F.J.; Garcinuño, * Correspondence:
[email protected]; Tel.: +34-659-496-544 S.; Lalueza, A.; Díaz-Simón, R.; † Collaborated equally as first co-authors. García-Reyne, A.; Pleguezuelo, D.E.; Cabrera-Marante, O.; Abstract: Background: COVID-19 clinical features include a hypercoagulable state that resembles Rodriguez-Frias, E.A.; Perez-Rivilla, the antiphospholipid syndrome (APS), a disease characterized by thrombosis and presence of an- A.; Serrano, M.; et al.